Description du projet
Le rôle du microbiote intestinal dans la prévention des maladies cardiovasculaires
Les maladies cardiovasculaires (MCV) sont l’une des principales causes de mortalité en Europe. Des études épidémiologiques et cliniques suggèrent que la consommation d’aliments contenant des polyphénols protège contre les MCV. Le microbiote intestinal apparait également comme un acteur essentiel dans la régulation de la bioactivité des polyphénols. Des essais cliniques récents ont indiqué que la composition du microbiote est importante pour l’efficacité des polyphénols. Le projet PolyBiota, financé par l’UE, apportera de nouvelles connaissances sur le rôle du microbiote intestinal en tant qu’acteur clé dans la prévention des maladies cardio-vasculaires grâce aux effets bénéfiques des aliments riches en polyphénols. La recherche se concentrera sur le rôle du microbiote intestinal en tant que médiateur des mécanismes associés à la prévention des maladies cardio-vasculaires et sur l’amélioration du traitement de ces dernières.
Objectif
Cardiovascular disease (CVD) is the main cause of mortality in Europe with an annual estimated cost of €210 billion. Different European Public Health strategies have targeted diet to prevent/treat CVDs. This multidisciplinary and multi-institutional project aims to provide new insights into the role of the gut microbiota as a key player in the beneficial effects against CVDs associated with the consumption of Polyphenols (PPs)-rich foods. PolyBiota will be developed through innovative research at one of the epicenters of PPs research (CEBAS-CSIC) and secondment at FISABIO (Valencia, Spain). Epidemiological, clinical, and preclinical studies suggest that the consumption of PPs-containing food protects against CVDs (i.e modulating angiogenesis in atherosclerotic plaques) . However, these benefits are not always observed due to the high inter-individual variability. The gut microbiota has emerged as an essential player that regulates the bioactivity of PPs. Recent clinical trials indicate that the gut microbiota composition play a critical role in the activity of PPs improving CV biomarkers. These studies open a new door to investigate how the interaction PPs-gut microbiota can modulate mechanisms associated with the improvement of CVDs. PolyBiota will investigate: i) role of the gut microbiota as mediator of the effects of the consumption of Ellagitannins (ETs)-/urolithin (Uro)-A- and Isoflavones (IsoFlv)-/equol-enriched diets on angiogenesis/mechanisms related in untreated and antibiotic-treated animals, ii) the “prebiotic-like effect” of the ETs, Uro-A, IsoFlv and equol consumption on the gut microbiota population, iii) the effects of the gut microbiota-biosynthesized messenguers or the ETs- and IsoFlv-derived metabolites on in vitro tubulogenesis. PolyBiota shows an innovative approach combining cutting-edge techniques, “big data” management, endothelial cells, and in vivo animal models providing a holistic scene of the Diet-Gut Microbiota-Host interaction.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
28006 Madrid
Espagne